Bristol-Myers Squibb Announces Worldwide Collaboration with Janssen
Bristol-Myers Squibb enters a worldwide collaboration with Janssen to develop and commercialize Bristol-Myers Squibb’s investigational Factor XIa inhibitor program.
Bristol-Myers Squibb Receives an FDA Approval
The most recent Bristol-Myers Squibb approval brings a new treatment option to certain patients with previously untreated advanced renal cell carcinoma.
Bristol-Myers Squibb and Nektar Therapeutics Enter Global Collaboration Agreement
The new $1.85 billion collaboration advances a strategic development partnership on a unique clinical-stage investigational immunotherapy agent.
Our R&D Team
Looking for Answers?
Quick links to helpful resources.